S. Srinivas

421 total citations
33 papers, 290 citations indexed

About

S. Srinivas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, S. Srinivas has authored 33 papers receiving a total of 290 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in S. Srinivas's work include Prostate Cancer Treatment and Research (10 papers), Cancer, Lipids, and Metabolism (7 papers) and Inflammatory mediators and NSAID effects (4 papers). S. Srinivas is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Cancer, Lipids, and Metabolism (7 papers) and Inflammatory mediators and NSAID effects (4 papers). S. Srinivas collaborates with scholars based in United States, India and Italy. S. Srinivas's co-authors include Louis J. DeTolla, Min Xu, Sanford A. Stass, Dhiren Kumar, Seon‐Mi Yu, A. James Mixson, Rohan Khandelwal, Chintamani Chintamani, Yashwant Kumar and Sidharth Jain and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

S. Srinivas

27 papers receiving 276 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Srinivas United States 8 125 94 81 50 49 33 290
Jacalyn B. Gano United States 9 152 1.2× 126 1.3× 65 0.8× 114 2.3× 27 0.6× 15 390
Anna Tomiak Canada 8 148 1.2× 97 1.0× 67 0.8× 54 1.1× 32 0.7× 11 331
Lajos Döbrőssy Hungary 10 176 1.4× 70 0.7× 26 0.3× 44 0.9× 20 0.4× 55 367
Robyn Y. Nishimi United States 7 119 1.0× 162 1.7× 89 1.1× 28 0.6× 37 0.8× 10 388
Jeffrey Feden United States 9 96 0.8× 153 1.6× 61 0.8× 37 0.7× 24 0.5× 10 319
Brianna Hoffner United States 9 153 1.2× 99 1.1× 56 0.7× 55 1.1× 12 0.2× 21 291
Elizabeth Philp United Kingdom 7 147 1.2× 184 2.0× 155 1.9× 32 0.6× 17 0.3× 8 426
Nancy Porter United States 12 138 1.1× 85 0.9× 52 0.6× 29 0.6× 7 0.1× 20 387
Christa Nagel United States 12 145 1.2× 83 0.9× 59 0.7× 43 0.9× 16 0.3× 47 529
Abdulazeez Salawu Canada 10 120 1.0× 48 0.5× 28 0.3× 91 1.8× 14 0.3× 28 266

Countries citing papers authored by S. Srinivas

Since Specialization
Citations

This map shows the geographic impact of S. Srinivas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Srinivas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Srinivas more than expected).

Fields of papers citing papers by S. Srinivas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Srinivas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Srinivas. The network helps show where S. Srinivas may publish in the future.

Co-authorship network of co-authors of S. Srinivas

This figure shows the co-authorship network connecting the top 25 collaborators of S. Srinivas. A scholar is included among the top collaborators of S. Srinivas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Srinivas. S. Srinivas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Bajpai, Jyoti, Gaurav Gupta, Bharat Rekhi, et al.. (2024). Evaluation of Metronomic Therapy as a Low-Cost, Sustainable, Standard-of-Care Option in Desmoid Fibromatosis: Real-World Data From a Tertiary Care Center in India. JCO Global Oncology. 10(10). e2300308–e2300308.
4.
Ramaswamy, Anant, Prabhat Bhargava, S. Srinivas, et al.. (2024). Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial. Journal of Clinical Oncology. 42(27). 3218–3227. 1 indexed citations
5.
6.
Ramaswamy, Anant, Anand V. Kulkarni, George John, et al.. (2023). Survival of Trial-Like and Non–Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP). JCO Global Oncology. 9(9). e2300215–e2300215. 4 indexed citations
7.
Ostwal, Vikas, Prabhat Bhargava, S. Srinivas, et al.. (2023). Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB). Journal of Clinical Oncology. 42(7). 800–807. 20 indexed citations
8.
Srinivas, S., et al.. (2021). Utility of Panfungal PCR in the diagnosis of invasive fungal infections in febrile neutropenia. SHILAP Revista de lepidopterología. 10(7). 2533–2540. 5 indexed citations
9.
Sivajothi, S., et al.. (2018). Diagnosis and Management of Equine Microfilariosis. INTAS POLIVET. 19(2). 226–227.
10.
Chintamani, Chintamani, Rohan Khandelwal, T. Megha, et al.. (2011). Patient and provider delays in breast cancer patients attending a tertiary care centre: a prospective study. JRSM Short Reports. 2(10). 1–4. 39 indexed citations
11.
Chintamani, Chintamani, Rohan Khandelwal, Sidharth Jain, et al.. (2011). The correlation of anxiety and depression levels with response to neoadjuvant chemotherapy in patients with breast cancer. JRSM Short Reports. 2(3). 1–5. 42 indexed citations
12.
Chintamani, Chintamani, JP Singh, Rohan Khandelwal, et al.. (2010). Vulval elephantiasis as a result of tubercular lymphadenitis: two case reports and a review of the literature. Journal of Medical Case Reports. 4(1). 369–369. 11 indexed citations
13.
Colocci, Natalia, et al.. (2007). Adjuvant docetaxel chemotherapy with abbreviated hormonal therapy in patients with high-risk prostate cancer. Journal of Clinical Oncology. 25(18_suppl). 15589–15589. 1 indexed citations
14.
George, C., David J. Vaughn, Daniel P. Petrylak, et al.. (2007). 4534 POSTER Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). European Journal of Cancer Supplements. 5(4). 309–309. 4 indexed citations
15.
Chang, Victor T., et al.. (2005). Validity, reliability and responsiveness of Euroqol (EQ5D) in patients (Pts) receiving palliative care (PC). Journal of Clinical Oncology. 23(16_suppl). 8082–8082. 9 indexed citations
16.
Kasimis, Basil, et al.. (2005). High dose celecoxib (C) and docetaxel (D) in patients (pts) with hormone resistant prostate cancer (HRPC). Results of an ongoing phase II trial. Journal of Clinical Oncology. 23(16_suppl). 4704–4704. 5 indexed citations
17.
Chang, Victor T., et al.. (2004). Clinically significant differences (CSD) in the Memorial Symptom Assessment Scale Short Form (MSAS-SF). Journal of Clinical Oncology. 22(14_suppl). 8269–8269. 1 indexed citations
18.
Yudd, Michael, et al.. (2004). Renal effects of high-dose celecoxib (CX) and docetaxel (D) During a phase II trial for hormone resistant prostate cancer (HRPC). Journal of Clinical Oncology. 22(14_suppl). 4752–4752. 8 indexed citations
19.
Chang, Victor T., et al.. (2004). Cancer pain: palliative care. Journal of Pain. 5(3). S49–S49. 2 indexed citations
20.
Xu, Min, Dhiren Kumar, S. Srinivas, et al.. (1997). Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors In Vivo Through a Bystander Mechanism Without Evidence of Toxicity. Human Gene Therapy. 8(2). 177–185. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacalyn B. Gano Breakdown of academic impact, for papers by Anna Tomiak Breakdown of academic impact, for papers by Lajos Döbrőssy Breakdown of academic impact, for papers by Robyn Y. Nishimi Breakdown of academic impact, for papers by Jeffrey Feden Breakdown of academic impact, for papers by Brianna Hoffner Breakdown of academic impact, for papers by Elizabeth Philp Breakdown of academic impact, for papers by Nancy Porter Breakdown of academic impact, for papers by Christa Nagel Breakdown of academic impact, for papers by Abdulazeez Salawu
Rankless by CCL
2026